GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Bohui Innovation Biotechnology Group Co Ltd (SZSE:300318) » Definitions » Goodwill-to-Asset

Beijing Bohui Innovation Biotechnology Group Co (SZSE:300318) Goodwill-to-Asset : 0.18 (As of Mar. 2025)


View and export this data going back to 2012. Start your Free Trial

What is Beijing Bohui Innovation Biotechnology Group Co Goodwill-to-Asset?

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Beijing Bohui Innovation Biotechnology Group Co's Goodwill for the quarter that ended in Mar. 2025 was ¥786.3 Mil. Beijing Bohui Innovation Biotechnology Group Co's Total Assets for the quarter that ended in Mar. 2025 was ¥4,381.6 Mil. Therefore, Beijing Bohui Innovation Biotechnology Group Co's Goodwill to Asset Ratio for the quarter that ended in Mar. 2025 was 0.18.


Beijing Bohui Innovation Biotechnology Group Co Goodwill-to-Asset Historical Data

The historical data trend for Beijing Bohui Innovation Biotechnology Group Co's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Bohui Innovation Biotechnology Group Co Goodwill-to-Asset Chart

Beijing Bohui Innovation Biotechnology Group Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Goodwill-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.31 0.22 0.20 0.20 0.19

Beijing Bohui Innovation Biotechnology Group Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Goodwill-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.20 0.19 0.19 0.18

Competitive Comparison of Beijing Bohui Innovation Biotechnology Group Co's Goodwill-to-Asset

For the Biotechnology subindustry, Beijing Bohui Innovation Biotechnology Group Co's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beijing Bohui Innovation Biotechnology Group Co's Goodwill-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beijing Bohui Innovation Biotechnology Group Co's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where Beijing Bohui Innovation Biotechnology Group Co's Goodwill-to-Asset falls into.


;
;

Beijing Bohui Innovation Biotechnology Group Co Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Beijing Bohui Innovation Biotechnology Group Co's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Goodwill to Asset (A: Dec. 2024 )=Goodwill/Total Assets
=786.272/4125.558
=0.19

Beijing Bohui Innovation Biotechnology Group Co's Goodwill to Asset Ratio for the quarter that ended in Mar. 2025 is calculated as

Goodwill to Asset (Q: Mar. 2025 )=Goodwill/Total Assets
=786.272/4381.584
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beijing Bohui Innovation Biotechnology Group Co  (SZSE:300318) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Beijing Bohui Innovation Biotechnology Group Co Goodwill-to-Asset Related Terms

Thank you for viewing the detailed overview of Beijing Bohui Innovation Biotechnology Group Co's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Beijing Bohui Innovation Biotechnology Group Co Business Description

Traded in Other Exchanges
N/A
Address
Block G Jingxinyuan, NO.25 Jia Beiwucun Road, Haidian, Beijing, CHN, 100097
Beijing Bohui Innovation Biotechnology Group Co Ltd is a high-tech biomedical enterprise integrating R&D, production, sales, and after-sales service. The company focuses on the research and development, production, sales, and after-sales services of in vitro diagnostic products. The Company's business involved two segments: inspection and testing and biological products. The Biological segment generated the majority of its revenue which engaged in the research and development, production, and sales of blood products, the product range covers human blood albumin, human immunoglobulin, and human coagulation factor three categories of multiple varieties, basically covering the important varieties of blood products.
Executives
Niu Shu Hui Executives
Di Xiao Feng Director
Yang Qi Director
Lu Xin Qun Directors, executives
Zhang Lei Director
Wan Zhang Geng Executives
Song Rui Directors, executives

Beijing Bohui Innovation Biotechnology Group Co Headlines

No Headlines